These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18240852)

  • 21. Stimulant treatment of ADHD and risk of sudden death in children.
    Vitiello B; Towbin K
    Am J Psychiatry; 2009 Sep; 166(9):955-7. PubMed ID: 19528196
    [No Abstract]   [Full Text] [Related]  

  • 22. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS; Genel M; Bezman RJ; Slanetz PJ
    JAMA; 1998 Apr; 279(14):1100-7. PubMed ID: 9546570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA-approved drugs to treat ADHD.
    J Psychosoc Nurs Ment Health Serv; 2013 Mar; 51(3):11-2. PubMed ID: 23452016
    [No Abstract]   [Full Text] [Related]  

  • 24. Measurement of growth in stimulant-naive children with attention-deficit/hyperactivity disorder by using cross-sectional and longitudinal approaches.
    Poulton A; Nanan R
    Pediatrics; 2008 Jul; 122(1):221; author reply 221-2. PubMed ID: 18596017
    [No Abstract]   [Full Text] [Related]  

  • 25. Persistence of stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Palli SR; Kamble PS; Chen H; Aparasu RR
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):139-48. PubMed ID: 22364400
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attitudes Toward Stimulant Treatment of Offspring of Adult Patients with Attention-Deficit/Hyperactivity Disorder.
    Canela C; Buadze A; Dube A; Eich D; Liebrenz M
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):422-428. PubMed ID: 28422527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of ADHD with stimulant medications: response to Nissen perspective in the New England Journal of Medicine.
    Biederman J; Spencer TJ; Wilens TE; Prince JB; Faraone SV
    J Am Acad Child Adolesc Psychiatry; 2006 Oct; 45(10):1147-1150. PubMed ID: 16840880
    [No Abstract]   [Full Text] [Related]  

  • 28. An update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorder.
    Chavez B; Sopko MA; Ehret MJ; Paulino RE; Goldberg KR; Angstadt K; Bogart GT
    Ann Pharmacother; 2009 Jun; 43(6):1084-95. PubMed ID: 19470858
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stimulants and sudden death: what is a physician to do?
    Wilens TE; Prince JB; Spencer TJ; Biederman J
    Pediatrics; 2006 Sep; 118(3):1215-9. PubMed ID: 16951018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation and Management of Elevated Blood Pressure in Children and Adolescents with Attention Deficit Hyperactivity Disorder.
    Yamaguchi I; Hanevold C
    Curr Hypertens Rep; 2019 Jun; 21(8):60. PubMed ID: 31218513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG; Perrin JM; Shelley-Abrahamson R; Wilens TE
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Attention deficit hyperactivity disorder medications in children with heart disease.
    Berger S
    Curr Opin Pediatr; 2016 Oct; 28(5):607-12. PubMed ID: 27261563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does stimulant medication decrease the lower extremity response times of children with and without attention-deficit/hyperactivity disorder?
    Brasić JR
    Percept Mot Skills; 2007 Feb; 104(1):67-8. PubMed ID: 17450965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Winterstein AG; Gerhard T; Shuster J; Johnson M; Zito JM; Saidi A
    Pediatrics; 2007 Dec; 120(6):e1494-501. PubMed ID: 18055666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].
    Golubchik P; Sever J; Weizman A
    Harefuah; 2011 Oct; 150(10):788-90, 814. PubMed ID: 22111124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of a hyperactive teen and cardiac safety.
    Sowinski H; Karpawich PP
    Pediatr Clin North Am; 2014 Feb; 61(1):81-90. PubMed ID: 24267459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What exactly are the benefits of stimulants for ADHD?
    Advokat C
    J Atten Disord; 2009 May; 12(6):495-8. PubMed ID: 19380518
    [No Abstract]   [Full Text] [Related]  

  • 39. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study.
    Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.